Attorney Docket No. PP19155.002 (35784/267827) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Wong et al.	Confirmation No.:	Not yet assigned
Appl. No.:	10/646,934	Art Unit:	Not yet assigned
Filed:	August 22, 2003	Examiner:	Not yet assigned
For:	COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED ANTIGEN MN/CA IX		

February 6, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Leslie T. Henry
Registration No. 45,714

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
on February 6, 2004

Lynda-Jo Pixley

Substitute for form 1449/PTO (Revised 04/2003)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/646,934
				Filing Date	August 22, 2003
				First Named Inventor	Wong
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	1	of	3	Attorney Docket Number	PP19155.002 (35784/267827)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-6,051,226	04-18-2000	Zavada *et al.*	
	2	US-6,204,370 B1	03-20-2001	Zavada *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	3	WO 01/60317 A2	08-23-2001	The Regents of the University of California		
	4	WO 01/98363 A2	12-27-2001	Katholieke Universiteit Nijmegen		
	5	WO 03/048328 A2	06-12-2003	Abgenix, Inc.		

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/646,934
				Filing Date	August 22, 2003
				First Named Inventor	Wong
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	3	Attorney Docket Number	PP19155.002 (35784/267827)

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	6	BEASLEY, N.J.P., *et al.*, "Carbonic Anhydrase IX, an Endogenous Hypoxia Marker, Expression in Head and Neck Squamous Cell Carcinoma and Its Relationship to Hypoxia, Necrosis, and Microvessel Density," *Cancer Research*, 2001, pp. 5262-5267, Vol. 61.	
	7	GRABMAIER, K., *et al.*, "Molecular Cloning and Immunogenicity of Renal Cell Carcinoma-Associated Antigen G250," *Int. J. Cancer*, 2000, pp. 865-870, Vol. 85.	
	8	IVANOV, S., *et al.*, "Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer," *American Journal of Pathology*, 2001, pp. 905-919, Vol. 158 (3).	
	9	LIAO, S.Y., *et al.*, "Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas," *American Journal of Pathology*, pp. 598-609, Vol. 145 (3).	
	10	LIAO, S.Y., *et al.*, "Identification of the MN/CA9 Protein as a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney," *Cancer Research*, 1997, pp. 2827-2831, Vol. (57).	
	11	LIESKOVSKA, J. "Study of *In Vitro* Conditions Modulating Expression of MN/CA IX Protein in Human Cell Lines Derived From Cervical Carcinoma," *Neoplasma*, 1999, pp. 17-24, Vol. 46 (1).	
	12	OPAVSKY, R., *et al.*, "Human *MN/CA9* Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships," Genomics, 1996, pp. 480-487, Vol. 33.	
	13	OOSTERWIJK, E., *et al.*, "The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma," *Seminars in Oncology*, 1995, pp. 34-41, Vol. 22 (1).	
	14	PASTOREK, J., *et al.*, "Cloning and Characterization of MN, a Human Tumor-Associated Protein with a Domain Homologous to Carbonic Anhydrase and a Putative Helix-Loop-Helix DNA Binding Segment, *Oncogene*, 1994, pp. 2877-2888, Vol. 9.	
	15	PASTOREKOVA, S., *et al.*, "Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts," *Gastroenterology*, 1997, pp. 398-408, Vol. 112.	
	16	SLY, W.S., and Hu, P.Y., "Human Carbonic Anhydrases and Carbonic Anhydrase Deficiencies," *Annu. Rev. Biochem.*, 1995, pp. 375-401, Vol. 64.	
	17	STEFFENS, M.G., *et al.*, "Tumor Retention of ^{186}Re-MAG3, ^{111}In-DTPA and ^{125}I Labeled Monoclonal Antibody G250 in Nude Mice with Renal Cell Carcinoma Xenografts," *Cancer Biotherapy & Radiopharmaceuticals*, 1998, pp. 133-139, Vol. 13 (2).	

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/646,934
				Filing Date	August 22, 2003
				First Named Inventor	Wong
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	3	of	3	Attorney Docket Number	PP19155.002 (35784/267827)

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	18	SUPURAN, C.T., *et al.*, "Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents?," *Bioorganic & Medicinal Chemistry*, 2001, pp. 703-714, Vol. 9.	
	19	TURNER, J.R., *et al.*, "MN Antigen Expression in Normal, Preneoplastic, and Neoplastic Esophagus: A Clinicopathological Study of a New Cancer-Associated Biomarker," *Human Pathology*, 1997, pp. 740-744, Vol. 28 (6).	
	20	UEMURA, H., *et al.*, "Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," *Int. J. Cancer*, 1994, pp. 609-614, Vol. 56.	
	21	VERMYLEN, P., *et al.*, "Carbonic Ahydrase IX Antigen Differentiates Between Preneoplastic Malignant Lesions in Non-Small Cell Lung Carcinoma," *Eur. Respir. J*, 1999, pp. 806-811, Vol. 14.	
	22	ZAVADA, J., *et al.*, "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens," *Int. J. Cancer*, 1993, pp. 268-274, Vol. 54.	

RTA01/2149344v1

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.